Unknown

Dataset Information

0

Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease.


ABSTRACT: Acquired, inactivating mutations in Tet methylcytosine dioxygenase 2 (TET2) are detected in peripheral blood cells of a remarkable 5%-10% of adults greater than 65 years of age. They impart a hematopoietic stem cell advantage and resultant clonal hematopoiesis of indeterminate potential (CHIP) with skewed myelomonocytic differentiation. CHIP is associated with an overall increased risk of transformation to a hematological malignancy, especially myeloproliferative and myelodysplastic neoplasms (MPN, MDS) and acute myeloid leukemia (AML), of approximately 0.5% to 1% per year. However, it is becoming increasingly possible to identify individuals at greatest risk, based on CHIP mutational characteristics. CHIP, and particularly TET2-mutant CHIP, is also a novel, significant risk factor for cardiovascular diseases, related in part to hyper-inflammatory, progeny macrophages carrying TET2 mutations. Therefore, somatic TET2 mutations contribute to myeloid expansion and innate immune dysregulation with age and contribute to prevalent diseases in the developed world-cancer and cardiovascular disease. Herein, we describe the impact of detecting TET2 mutations in the clinical setting. We also present the rationale and promise for targeting TET2-mutant and other CHIP clones, and their inflammatory environment, as potential means of lessening risk of myeloid cancer development and dampening CHIP-comorbid inflammatory diseases.

SUBMITTER: Ferrone CK 

PROVIDER: S-EPMC7014315 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Age-Associated <i>TET2</i> Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease.

Ferrone Christina K CK   Blydt-Hansen Mackenzie M   Rauh Michael J MJ  

International journal of molecular sciences 20200117 2


Acquired, inactivating mutations in Tet methylcytosine dioxygenase 2 (<i>TET2</i>) are detected in peripheral blood cells of a remarkable 5%-10% of adults greater than 65 years of age. They impart a hematopoietic stem cell advantage and resultant clonal hematopoiesis of indeterminate potential (CHIP) with skewed myelomonocytic differentiation. CHIP is associated with an overall increased risk of transformation to a hematological malignancy, especially myeloproliferative and myelodysplastic neopl  ...[more]

Similar Datasets

| S-EPMC5826570 | biostudies-other
2020-03-12 | GSE146812 | GEO
2009-05-28 | GSE15688 | GEO
| S-EPMC7901355 | biostudies-literature
2023-08-09 | GSE225859 | GEO
| S-EPMC7083427 | biostudies-literature
| S-EPMC9099391 | biostudies-literature
| S-EPMC3188678 | biostudies-literature
| S-EPMC5034469 | biostudies-literature
| S-EPMC3678527 | biostudies-literature